Prime Medicine

Prime Medicine

Biotechnology
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

$645.8M

Market Cap • 11/20/2026

2019

(7 years)

Founded

2022

(4 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

76,5

P/S

91,5

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0

EPS

—

Market Cap

Market Cap

645,8M

EV

695,1M

EV/Revenue

98,4

EV/EBITDA

-4

EV/EBIT

-3,8

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,6%

Total Yield

-0,6%

Payout

0%

Retained Earnings

-1B

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

1930,7%

Capex/Revenue

12%

Capex/D&A

11,7%

Capex/OCF

-0,5%

SBC/OCF

—

% PPE

62,3%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

46,5%

CAGR Net Income 5Y

10,9%

CAGR EPS 5Y

-23,1%

CAGR OCF 5Y

46,5%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

1,8

Quick Ratio

1,7

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium